Anders Christensson

Prof. Dr. Anders Christensson

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2019 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
PDPierre Delanaye
Pierre Delanaye
KJKitty J. Jager
Kitty J. Jager
ABArend Bökenkamp
Arend Bökenkamp
ACAnders Christensson
Anders Christensson
LDLaurence Dubourg
Laurence Dubourg
JBJan A. J. G. van Den Brand
Jan A. J. G. van Den Brand
Current criteria for the diagnosis of CKD in adults include persistent signs of kidney damage, such as increased urine albumin-to-creatinine ratio or a GFR below the threshold of 60 ml/min per 1.73 m2. This threshold has important caveats because it does not separate kidney disease from kidney aging, and therefore does not hold for all ages. In an extensive review of the literature, we found that GFR declines with healthy aging without any overt signs of compensation (such as elevated single-nephron GFR) or kidney damage. Older living kidney donors, who are carefully selected based on good health, have a lower predonation GFR compared with younger donors. Furthermore, the results from the large meta-analyses conducted by the CKD Prognosis Consortium and from numerous other studies indicate that the GFR threshold above which the risk of mortality is increased is not consistent across all ages. Among younger persons, mortality is increased at GFR <75 ml/min per 1.73 m2, whereas in elderly people it is increased at levels <45 ml/min per 1.73 m2. Therefore, we suggest that amending the CKD definition to include age-specific thresholds for GFR. The implications of an updated definition are far reaching. Having fewer healthy elderly individuals diagnosed with CKD could help reduce inappropriate care and its associated adverse effects. Global prevalence estimates for CKD would be substantially reduced. Also, using an age-specific threshold for younger persons might lead to earlier identification of CKD onset for such individuals, at a point when progressive kidney damage may still be preventable.

7 December 2022 in Journal of Internal Medicine
Verified
Journal Article
Open access
LMLinnea Malmgren
Linnea Malmgren
CÖCarl Öberg
Carl Öberg
EBEmil Den Bakker
Emil Den Bakker
FLFelicia Leion
Felicia Leion
JSJoanna Siódmiak
Joanna Siódmiak
AGAnders Grubb
Anders Grubb
Estimation of kidney function is often part of daily clinical practice, mostly done by using the endogenous glomerular filtration rate (GFR)‐markers creatinine or cystatin C. A recommendation to use both markers in parallel in 2010 has resulted in new knowledge concerning the pathophysiology of kidney disorders by the identification of a new set of kidney disorders, selective glomerular hypofiltration syndromes. These syndromes, connected to strong increases in mortality and morbidity, are characterized by a selective reduction in the glomerular filtration of 5–30 kDa molecules, such as cystatin C, compared to the filtration of small molecules <1 kDa dominating the glomerular filtrate, for example water, urea and creatinine. At least two types of such disorders, shrunken or elongated pore syndrome, are possible according to the pore model for glomerular filtration. Selective glomerular hypofiltration syndromes are prevalent in investigated populations, and patients with these syndromes often display normal measured GFR or creatinine‐based GFR‐estimates. The syndromes are characterized by proteomic changes promoting the development of atherosclerosis, indicating antibodies and specific receptor‐blocking substances as possible new treatment modalities. Presently, the KDIGO guidelines for diagnosing kidney disorders do not recommend cystatin C as a general marker of kidney function and will therefore not allow the identification of a considerable number of patients with selective glomerular hypofiltration syndromes. Furthermore, as cystatin C is uninfluenced by muscle mass, diet or variations in tubular secretion and cystatin C‐based GFR‐estimation equations do not require controversial race or sex terms, it is obvious that cystatin C should be a part of future KDIGO guidelines.

5 March 2013 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
ACAnders Christensson
Anders Christensson
CSCaroline Savage
Caroline Savage
DSDaniel D. Sjoberg
Daniel D. Sjoberg
ACAngel M. Cronin
Angel M. Cronin
MOM. Frank O'BRien
M. Frank O'BRien
HLHans Lilja
Hans Lilja
Patients with chronic renal failure show a greater incidence of malignancies. We evaluated whether moderately impaired renal function at baseline influenced risk of all cancers during long‐term follow in young persons. Our cohort included 33,346 subjects, aged 26–61 years at baseline, in a representative, population‐based study enrolling subjects from 1974 to 1992. Median follow‐up time was 28 years. Plasma creatinine was analyzed as a single measure at baseline. Incident cases of cancer were identified from the Swedish Cancer Registry. We studied 24,552 subjects from the cohort. To account for the unique sampling design, participants were divided by sex and age at baseline into 1,132 older men (age 60), 14,254 younger men (age 40–52), 7,498 older women (age 47–57) and 1,688 younger women (age 35–43). Glomerular filtration rate (GFR) was estimated using the CKD‐EPI formula. Patients were classified as having either normal to mildly impaired kidney function (eGFR ≥ 60 mL/min/1.73 m2), or moderate kidney dysfunction (eGFR<60 mL/min/1.73 m2). We calculated the risk of all cancers using competing risks regression. Overall, 6,595 participants were diagnosed with cancer, and 854 subjects (3.5%) had moderately impaired renal dysfunction at baseline. There was a significant association between moderately decreased GFR and subsequent risk of kidney cancer in younger men (hazard ratio, 3.38; 95% CI, 1.48 to 7.71; p = 0.004). However, we found no association with overall long‐term cancer risk. Our confirmation of an association between moderately impaired renal function and risk of kidney cancer in younger men requires further exploration of high‐risk groups and biological mechanisms.

9 October 2013 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
GGGunilla Grundström
Gunilla Grundström
ACAnders Christensson
Anders Christensson
MAMaria Alquist
Maria Alquist
LNLars-Göran Nilsson
Lars-Göran Nilsson
MSMårten Segelmark
Mårten Segelmark
The majority of bicarbonate based dialysis fluids are acidified with acetate. Citrate, a well known anticoagulant and antioxidant, has been suggested as a biocompatible alternative. The objective of this study was to evaluate short term safety and biocompatibility of a citrate containing acetate-free dialysis fluid.

31 January 2018 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
PDF file
ACAnders Christensson
Anders Christensson
JAJessica A. Ash
Jessica A. Ash
RDRobert K. DeLisle
Robert K. DeLisle
FGFraser W. Gaspar
Fraser W. Gaspar
RORachel Ostroff
Rachel Ostroff
SWSteve A. Williams
Steve A. Williams

13 September 2016 in Scandinavian Journal of Clinical and Laboratory Investigation
Verified
Journal Article
Closed access
ACAnders Christensson
Anders Christensson
AGAnders Grubb
Anders Grubb
JMJohn Molvin
John Molvin
HHHannes Holm
Hannes Holm
KGKlas Gransbo
Klas Gransbo
MMMartin Magnusson
Martin Magnusson
The close relationship between heart and kidney diseases was studied with respect to the ‘Shrunken pore syndrome’ that is characterized by a difference in renal filtration between cystatin C and creatinine. Patients were retrieved from the HeARt and brain failure inVESTigation trail (HARVEST) which is an ongoing study undertaken in individuals hospitalized for the diagnosis of heart failure. Ninety-five of 116 patients who underwent transthoracic echocardiograms (TTE) were eligible for this study. We used four different formulas for estimated glomerular filtration rate (eGFR); CKD-EPIcreatinine, CKD-EPIcystatin C, LMrev and CAPA. Presence of the syndrome was defined as eGFR cystatin C ≤ 60% of eGFR creatinine and absence of the syndrome as eGFR cystatin C >90% and <110% of eGFR creatinine. In a linear regression model, adjusted for age and sex, and the ‘Shrunken pore syndrome’ defined by the equation pair CAPA and LMrev and the equation pair CKD-EPIcystatin C and CKD-EPIcreatinine, echocardiographic parameters were studied. The ‘Shrunken pore syndrome’ showed statistically significant associations with measurements of right ventricular (RV) systolic function; (TAPSE and RV S’) (according to the equation pair CKD-EPIcystatin C and CKD-EPIcreatinine). In conclusion, heart failure patients with the ‘Shrunken pore syndrome’ are at increased risk of having RV systolic dysfunction whilst heart failure patients without ‘Shrunken pore syndrome’ seem protected. These findings may indicate common pathophysiological events in the kidneys and the heart explaining the observed increased risk of mortality in subjects with the ‘Shrunken pore syndrome’.